Close menu

April 13th, 2021 | 09:06 CEST

InnoCan Pharma, Cardiol Therapeutics, BevCanna - Watch out: undiscovered cannabis price rockets!

  • Biotechnology
Photo credits:

Whether French explorer Jacques Cartier, who first named the region around present-day Quebec "Canada" in 1535, was acting on a hunch, or simply "Frenching" the word "Kanata" from the language of the Saint Lawrence Iroquois, can unfortunately no longer be determined with certainty today. However, what is certain is that today's "Canada" is the current stronghold of medical "cannabis." Thanks to liberal laws, hemp startups are sprouting up worldwide, and even established companies want a piece of the pie. Here are three interesting candidates for the portfolio, with current news and powerful price potential!

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: CA45783P1027 , CA14161Y2006 , CA08783B1013

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    InnoCan Pharma - Innovative injection system for CBD-based pharmaceuticals

    InnoCan Pharma focuses on the development of platforms for the delivery of cannabidiol (CBD)-based pharmaceuticals. The Canadian Company's research and development activities take place exclusively in Israel. CBD-integrated medicines are additionally researched and developed there. InnoCan Pharma focuses on a few narrowly defined fields: diseases caused by viruses, such as Covid-19 or other types of pneumonia, as well as diseases of the central nervous system, such as epilepsy; the topic of effective relief of rheumatic muscle pain; and the treatment of psoriasis.

    With regard to its delivery platforms, the Company has developed a revolutionary and patent-pending injection system based on cannabidiol-loaded liposomes that enable targeted and controlled drug release. Currently, there are 15 liposomal drugs approved by the US Food and Drug Administration, while many more are currently in international trials. InnoCan plans to combine steroid drugs with cannabidiols, which are proven to provide lower steroid concentrations and deliver them to targeted disease sites using the liposomal injection method to best dose the active ingredient. InnoCan was recently able to report its figures for the past fiscal year. The Company succeeded in raising CAD 6.2 million in new funds from January to December 2020. In addition, CAD 3.8 million was raised through the exercise of warrants. At the end of the year, the cash balance was approximately CAD 2.9 million with approximately CAD 1.3 million in liabilities.

    Six patent applications were filed in the last fiscal year. Currently, the stock is trading at CAD 0.55, giving the Company a market capitalization of CAD 108 million. Two drugs have entered the animal testing phase, so there is still a long way to go before approval. If you are willing to take risks and have patience, you should take a closer look at the stock.

    Cardiol Therapeutics - Many arrows in the quiver

    Cardiol Therapeutics is also fully committed to CBD. However, it is a particularly pure form of CBD, without any THC normally inherent in the cannabis plant. And for good reason: the focus is on heart diseases, so-called Cardiovascular disease (CVD) in younger and especially older patients, and patients who cannot tolerate THC or are prohibited due to occupational requirements. The THC content in the cannabidiol products used has been reduced to less than 10ppm (ppm = parts per million, i.e. 10 THC molecules to 1,000,000 other molecules). This amount is practically below the detection threshold. Currently, Cardiol Therapeutics' portfolio consists of three therapies in development and the approved product Cortalex, a high-dose CBD concentrate for oral administration. One of the products in the product pipeline is CardiolRX.

    Yesterday, the Company reported results from a recent Phase I study. The study was a randomized, placebo-controlled, double-blind study evaluating the safety, tolerability and pharmacokinetic profile of CardiolRx at different dose levels. The study tested 52 subjects (age range 25 to 60 years). The results showed that CardiolRx was safe and generally well-tolerated at all dose levels. While this is good news for shareholders, it also suggests positive results in international studies. In addition, CardiolRx is being investigated for its suitability as a therapy for Covid-19 patients and its area of use in CVD, as CVD patients have a much higher risk of death from SARS-CoV2 infection. Another research area is acute myocarditis, or spontaneous inflammation of the heart muscle, which is the most common cause of infarction in patients under 35 years of age with cardiac arrest.

    Cardiol Therapeutics was also recently able to present its figures for fiscal 2020. Characteristically, young companies generate losses (CAD 20.6 million) and invest heavily in research and development (CAD 10.5 million). An important aspect is refinancing via the capital market. The cash balance at the end of the year was a comfortable CAD 14 million. In 2021, Cardiol plans to list on NASDAQ. This should push the valuation of the Company (currently: CAD 160 million) up significantly. The stock is traded on the TSX and in Frankfurt. With the convincing portfolio and the targeted dual listing, the share should continue to climb this year. Analysts at Leede Jones Gable currently estimate the share price potential at CAD 12.50.

    BevCanna - White label beverage production with a special kick

    BevCanna Enterprises designs and produces "cannabis-infused drinks" and is also active in this area as a white label manufacturer. According to a study by Grand View Research, the Canadian Company is thus in a very fast-growing market. Grand View forecasts a market volume of an impressive USD 2.8 billion for cannabis-infused drinks by 2025. That translates to an annual growth rate of about 18% from 2020 to 2025.

    But with a lot of growth and potential, the number of competitors usually increases as well. BevCanna is gearing up for the looming competition in its own way: just last December, it merged with Naturo, a Company with which it had already had an intensive partnership for some time. Valued at around USD 40 million, the Company has since been run as a 100% subsidiary of BevCanna. Naturo brought an extremely valuable gift into the marriage: its alkaline water source, which experts value at USD 18 million. Back in September, BevCanna was able to acquire online direct sales specialist Naturally Pure Therapy. The natural health and wellness products shipper continued its strong 2020 revenue growth in the first quarter of 2021. In the process, the Company acquired more than 3,000 new customers thanks to its affiliation with BevCanna.

    In January, BevCanna also completed a CAD 5 million capital increase at prices of CAD 1.50, well above market levels. The high demand proves that investors believe in the future of the Company. In addition, the Canadians received CAD 1.5 million through the exercise of warrants. The share has corrected significantly in recent weeks and is trading at just under CAD 0.90. The share price decline offers a favorable opportunity to invest in the well-positioned Company in a growth market. The stock market value of around CAD 87 million leaves room for increases.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Armin Schulz on February 12th, 2024 | 07:00 CET

    MorphoSys, Defence Therapeutics, Bayer - Biotech and Pharma suddenly back in focus

    • Biotechnology
    • Pharma

    Biotech ETFs have been on the rise since the end of October 2023. German biotech companies were able to raise more funds again last year. There are increasing signs that the tough times for investors in biotech and pharmaceutical companies are over. There is also growing activity on the takeover side. Most recently, the takeover bid from Novartis shifted the focus to companies in the healthcare sector. The Swiss pharmaceutical company wants to acquire MorphoSys for EUR 2.7 billion and thus fill up its oncology pipeline. We have selected three companies from the biotech and pharma sectors and examined their current situation.